Mutations in α-chain of C4BP that selectively affect its factor I cofactor function

被引:30
作者
Blom, AM
Villoutreix, BO
Dahlbäck, B
机构
[1] Lund Univ, Dept Clin Chem, Malmo Univ Hosp, Wallenberg Lab, S-20502 Malmo, Sweden
[2] Univ Paris 06, INSERM, U428, F-75006 Paris, France
关键词
D O I
10.1074/jbc.M306620200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
C4b-binding protein (C4BP) inhibits all pathways of complement activation, acting as a cofactor to the serine protease factor I (FI) in the degradation of activated complement factors C4b and C3b. C4BP is a disulfide-linked polymer of seven alpha-chains and a unique beta-chain, the alpha- and beta-chains being composed of eight and three complement control protein (CCP) domains, respectively. In previous studies we have localized cofactor activity and binding of C4b to alpha-chain CCP1-3 of C4BP, whereas the binding of C3b required additionally CCP4. Likewise, introduced point mutations that decreased binding of C4b/C3b caused a decrease in cofactor activity. In the present study, we describe two mutants of C4BP, K126Q/K128Q and F144S/F149S, clustered on alpha-chain CCP3, which selectively lost their ability to act as cofactors in the cleavage of both C4b and C3b. Both mutants show the same binding affinity for C4b/C3b as measured by surface plasmon resonance and have the same inhibitory effect on formation and decay of the classical pathway C3-convertase as the wild type C4BP. It appears that C4b and C3b do not undergo the same conformational changes upon binding to the C4BP mutants as during the interaction with the wild type C4BP, which then results in the observed loss of the cofactor activity.
引用
收藏
页码:43437 / 43442
页数:6
相关论文
共 46 条
[31]   SITES WITHIN THE COMPLEMENT C3B C4B RECEPTOR IMPORTANT FOR THE SPECIFICITY OF LIGAND-BINDING [J].
KRYCH, M ;
HOURCADE, D ;
ATKINSON, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (10) :4353-4357
[32]   Structure-function analysis of the active sites of complement receptor type 1 [J].
Krych, M ;
Hauhart, R ;
Atkinson, JP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (15) :8623-8629
[33]  
KRYCH M, 1994, J BIOL CHEM, V269, P13273
[34]   Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H [J].
Kuhn, S ;
Zipfel, PF .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (10) :2383-2387
[35]  
KUHN S, 1995, J IMMUNOL, V155, P5663
[36]   Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46) [J].
Liszewski, MK ;
Leung, M ;
Cui, WY ;
Subramanian, VB ;
Parkinson, J ;
Barlow, PN ;
Manchester, M ;
Atkinson, JP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (48) :37692-37701
[37]   Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35) [J].
Oran, AE ;
Isenman, DE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (08) :5120-5130
[38]   A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1 [J].
Prasadarao, NV ;
Blom, AM ;
Villoutreix, BO ;
Linsangan, LC .
JOURNAL OF IMMUNOLOGY, 2002, 169 (11) :6352-6360
[39]   Binding of C4b-binding protein:: A molecular mechanism of serum resistance of Neisseria gonorrhoeae [J].
Ram, S ;
Cullinane, M ;
Blom, AM ;
Gulati, S ;
McQuillen, DP ;
Monks, BG ;
O'Connell, C ;
Boden, R ;
Elkins, C ;
Pangburn, MK ;
Dahlbäck, B ;
Rice, PA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (03) :281-295
[40]  
RUDDY S, 1971, J IMMUNOL, V107, P742